Ultra-high speed AO-OCT clinical system to image ganglion cells and microglia

超高速 AO-OCT 临床系统对神经节细胞和小胶质细胞进行成像

• 批准号: 10547181
• 负责人: Mircea Mujat
• 金额: $ 87.56万
• 依托单位: PHYSICAL SCIENCES, INC
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-30 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10547181
• 关键词: Area; Biological Markers; Blindness; Buffers; Cells; Clinical; Collaborations; Communities; Data; Degenerative Disorder; Detection; Development; Diabetes Mellitus; Diabetic Retinopathy; Diagnosis; Disease; Disease Marker; Disease Progression; Ear; Elements; Evaluation; Eye; Ganglia; Glaucoma; Goals; Government; Human; Image; Imaging Techniques; Investigation; Label; Lateral; Lead; Legal patent; Market Research; Massachusetts; Microglia; Monitor; Morphologic artifacts; Motion; Nerve Fibers; Neurosciences; Noise; Ophthalmology; Ophthalmoscopes; Optics; Pathogenesis; Patients; Performance; Persons; Phagocytosis; Pharmacotherapy; Phase; Play; Recording of previous events; Research; Resolution; Retina; Retinal Degeneration; Retinal Diseases; Retinal Ganglion Cells; Role; Scanning; Severity of illness; Signal Transduction; Source; Spatial Distribution; Speed; Structure; System; Technology; Testing; Time; Vision; adaptive optics; axon injury; base; clinical diagnostics; clinical imaging; cost; density; design; diagnostic platform; experience; ganglion cell; healthy volunteer; human subject; imager; imaging approach; imaging platform; imaging system; improved; improved functioning; innovation; instrument; interest; lens; macrophage; next generation; novel; novel therapeutics; optical imaging; physical science; programs; prototype; retinal imaging; routine imaging; specific biomarkers; tool

Project Summary/Abstract There is currently a significant need for new imaging techniques that may enable accurate quantification of biomarkers for detection, diagnosis, and monitoring of retinal diseases progression. Physical Sciences Inc. (PSI), Massachusetts Eye and Ear (MEE), and Joslin Diabetes Center (JDC) propose to develop a clinical tool able to routinely image retinal ganglion cells (RGCs) and to characterize microglia spatial distribution and temporal dynamics in live human eyes using a label-free adaptive optics (AO) imaging approach for improved diagnosis and treatment of glaucoma and diabetic retinopathy (DR). An ultra-high speed AO-OCT system will be designed and built based on a number of recently demonstrated innovations: lens-based design, ultra-high speed to eliminate motion artifacts, buffered swept source (SS) and dual beam approach to increase A-line rate to the MHz range, adaptive lens, dual-axis MEMS for raster scanning, and the use of polarization optics to eliminate specular reflections on optical elements. The retinal imager will be tested in a clinical setting at MEE and JDC on a large group of glaucoma and DR subjects experiencing a wide range of disease severity. Specific biomarkers for glaucoma and DR will be defined based on patient data acquired by our collaborators from MEE and JDC. PSI has a long, successful history of developing and commercializing high-resolution retinal imagers for the ophthalmic research market which gives us a competitive advantage in developing and maturing this platform that enables routine clinical imaging of human subjects and motivates a Direct to Phase II approach. A successful program and subsequent Phase III commercial development will provide clinicians with high performance retinal imaging for glaucoma and DR investigations at a lower cost and improved functionality superior to other non-AO retinal imagers. Early adaptors of this technology within the research community will grow our understanding of vision and its disruption by glaucoma and DR and will investigate the effects of new drugs and therapies. The ability to visualize ganglion and macrophage cells without fluorescent labeling in the human eye represents an important advance for both ophthalmology and neuroscience, which will lead to identification of novel disease biomarkers and new avenues of exploration in disease progression.

项目摘要/摘要 目前对新成像技术有很大的需求，可以准确 定量生物标志物进行检测，诊断和监测视网膜疾病的进展。 物理科学公司（PSI），马萨诸塞州的眼睛和耳朵（MEE）和乔斯林糖尿病中心（JDC） 建议开发能够常规图像视网膜神经节细胞（RGC）的临床工具并表征 使用无标签的自适应光学元件，在人眼中的小胶质细胞空间分布和时间动力学 （AO）改善青光眼和糖尿病性视网膜病（DR）的诊断和治疗的成像方法。 将根据许多最近设计和构建超高的速度AO-O-OCT系统 展示的创新：基于镜头的设计，消除运动伪像的超高速度，缓冲 来源（SS）和双光束方法，将A线速率提高到MHz范围，自适应镜头，双轴 用于栅格扫描的MEMS，并使用极化光学器件消除光学上的镜面反射 元素。视网膜成像仪将在MEE和JDC的临床环境中进行测试 青光眼和DR受试者患有广泛的疾病严重程度。青光眼的特定生物标志物 并将根据MEE和JDC的合作者获取的患者数据来定义DR。 PSI在开发和商业化高分辨率视网膜成像器的历史上有悠久的历史 眼科研究市场，使我们在开发和成熟方面具有竞争优势 实现人类受试者的常规临床成像并激励直接进入II期的平台 方法。成功的计划和随后的III期商业发展将为临床医生提供 高性能视网膜成像用于青光眼和DR调查，成本较低，并改善 功能优于其他非AO视网膜成像仪。研究中该技术的早期适配器 社区将对视力及其对视觉的理解及其破坏。 新药和疗法的影响。可以看到神经节和巨噬细胞的能力 人眼中的荧光标记代表着眼科和 神经科学将导致鉴定新型疾病生物标志物和新的勘探途径 在疾病进展中。